迷幻药物,和发作:一个回顾
Ninon Freidel1,2, Liliane Kreuder1,3, Brenden Samuel Rabinovitch1,4,5
1Department of Clinical Research, Numinus Toronto, Toronto, ON, Canada.
迷幻药对神经系统疾病有前途,但排除了患者. 这篇评论表明,在临床环境中,精神病辅助疗法可能对患有发作障碍的人来说是安全的.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 迷幻化合物具有历史和现代临床应用.
- 目前的临床试验排除了有史的个体,限制了治疗选择.
- 缺乏证据表明迷幻药会诱发或加重发作.
研究的目的:
- 审查精神类药物在患有发作障碍的人群中使用的安全性.
- 为了探索在这个人群中心理辅助治疗的潜力.
- 确定未来的研究方向.
主要方法:
- 对现有临床试验和临床前模型的文献综述.
- 对涉及迷幻药物使用和活动的案例研究的分析.
- 检查心理药物管理后发作结果的趋势.
主要成果:
- 没有临床或临床前证据表明迷幻药会引起发作.
- 案例研究显示了多种结果,包括缓解.
- 总体趋势表明,在受控,监督的环境中安全.
结论:
- 心理辅助疗法可能是患有发作障碍的患者的可行选择.
- 当前试验中的排除标准可能是不必要的限制.
- 需要进一步的研究来证实该群体的安全性和有效性.
更多相关视频
06:45Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
Published on: January 19, 2019
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
相关概念视频
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Hallucinogens and Psychedelics
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Electroconvulsive Therapy
Antiepileptic Drugs: Glutamate Antagonists
